JP2567427B2 - 浸透分配経口投与製剤 - Google Patents
浸透分配経口投与製剤Info
- Publication number
- JP2567427B2 JP2567427B2 JP62285627A JP28562787A JP2567427B2 JP 2567427 B2 JP2567427 B2 JP 2567427B2 JP 62285627 A JP62285627 A JP 62285627A JP 28562787 A JP28562787 A JP 28562787A JP 2567427 B2 JP2567427 B2 JP 2567427B2
- Authority
- JP
- Japan
- Prior art keywords
- metoprolol
- salt
- core
- weight
- osmotically
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 230000003204 osmotic effect Effects 0.000 title claims abstract description 13
- 238000009472 formulation Methods 0.000 title claims abstract description 11
- 238000005192 partition Methods 0.000 title claims 3
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical class COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims abstract description 42
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 claims abstract description 12
- 229920002301 cellulose acetate Polymers 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 19
- 239000012528 membrane Substances 0.000 claims description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 13
- 229960002237 metoprolol Drugs 0.000 claims description 12
- BRIPGNJWPCKDQZ-WXXKFALUSA-N (e)-but-2-enedioic acid;1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol Chemical group OC(=O)\C=C\C(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 BRIPGNJWPCKDQZ-WXXKFALUSA-N 0.000 claims description 10
- 229960002005 metoprolol fumarate Drugs 0.000 claims description 10
- 230000002496 gastric effect Effects 0.000 claims description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 3
- 239000006186 oral dosage form Substances 0.000 claims 3
- 239000000463 material Substances 0.000 abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 10
- 239000004480 active ingredient Substances 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000003763 resistance to breakage Effects 0.000 abstract 1
- 239000007909 solid dosage form Substances 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 9
- 229940069328 povidone Drugs 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- GJAYYEWRFJQMQK-UHFFFAOYSA-N acetic acid;ethyl carbamate Chemical compound CC(O)=O.CCOC(N)=O GJAYYEWRFJQMQK-UHFFFAOYSA-N 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000006082 mold release agent Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920008347 Cellulose acetate propionate Polymers 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920003072 Plasdone™ povidone Polymers 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- PHZNAJGHSKSUOZ-UHFFFAOYSA-N acetic acid;2-(dimethylamino)acetic acid Chemical compound CC(O)=O.CN(C)CC(O)=O PHZNAJGHSKSUOZ-UHFFFAOYSA-N 0.000 description 1
- WOOJRPBCEMEHLS-UHFFFAOYSA-N acetic acid;butane-1-sulfonic acid Chemical compound CC(O)=O.CCCCS(O)(=O)=O WOOJRPBCEMEHLS-UHFFFAOYSA-N 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- IIOPVJIGEATDBS-UHFFFAOYSA-N acetic acid;dodecanoic acid Chemical compound CC(O)=O.CCCCCCCCCCCC(O)=O IIOPVJIGEATDBS-UHFFFAOYSA-N 0.000 description 1
- ZXPJBQLFCRVBDR-UHFFFAOYSA-N acetic acid;methanesulfonic acid Chemical compound CC(O)=O.CS(O)(=O)=O ZXPJBQLFCRVBDR-UHFFFAOYSA-N 0.000 description 1
- MFOPEVCFSVUADB-UHFFFAOYSA-N acetic acid;methyl carbamate Chemical compound CC(O)=O.COC(N)=O MFOPEVCFSVUADB-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000464 adrenergic agent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- -1 alkyl glycidyl ethers Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- NEHMKBQYUWJMIP-NJFSPNSNSA-N chloro(114C)methane Chemical compound [14CH3]Cl NEHMKBQYUWJMIP-NJFSPNSNSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000003618 dip coating Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- HDERJYVLTPVNRI-UHFFFAOYSA-N ethene;ethenyl acetate Chemical class C=C.CC(=O)OC=C HDERJYVLTPVNRI-UHFFFAOYSA-N 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229960001300 metoprolol tartrate Drugs 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- WUBVEMGCQRSBBT-UHFFFAOYSA-N tert-butyl 4-(trifluoromethylsulfonyloxy)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(=O)(=O)C(F)(F)F)=CC1 WUBVEMGCQRSBBT-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93082886A | 1986-11-14 | 1986-11-14 | |
| US930828 | 1986-11-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63135329A JPS63135329A (ja) | 1988-06-07 |
| JP2567427B2 true JP2567427B2 (ja) | 1996-12-25 |
Family
ID=25459837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62285627A Expired - Lifetime JP2567427B2 (ja) | 1986-11-14 | 1987-11-13 | 浸透分配経口投与製剤 |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0271438B1 (enExample) |
| JP (1) | JP2567427B2 (enExample) |
| KR (1) | KR960002180B1 (enExample) |
| AT (1) | ATE75394T1 (enExample) |
| AU (1) | AU598318B2 (enExample) |
| CA (1) | CA1312016C (enExample) |
| DE (1) | DE3778662D1 (enExample) |
| DK (1) | DK595987A (enExample) |
| ES (1) | ES2032205T3 (enExample) |
| GR (1) | GR3005132T3 (enExample) |
| IE (1) | IE60533B1 (enExample) |
| NZ (1) | NZ222525A (enExample) |
| PT (1) | PT86119B (enExample) |
| ZA (1) | ZA878526B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4892739A (en) * | 1988-04-25 | 1990-01-09 | Ciba-Geigy Corporation | Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having a improved core membrane adhesion properties |
| US4859470A (en) * | 1988-06-02 | 1989-08-22 | Alza Corporation | Dosage form for delivering diltiazem |
| KR100733925B1 (ko) * | 2005-03-16 | 2007-07-02 | 주식회사 엘지화학 | ＥＣＤ(Ｅｌｅｃｔｒｏ Ｃｈｒｏｍｉｃ Ｄｅｖｉｃｅ) 제어 장치 |
| IL210279A0 (en) | 2009-12-25 | 2011-03-31 | Dexcel Pharma Technologies Ltd | Extended release compositions for high solubility, high permeability acdtive pharmaceutical ingredients |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4576604A (en) * | 1983-03-04 | 1986-03-18 | Alza Corporation | Osmotic system with instant drug availability |
| GB8503666D0 (en) * | 1985-02-13 | 1985-03-13 | Shell Int Research | Producing 4-(2-methoxyethyl)-phenylglycidyl ether |
| US5019302A (en) * | 1986-03-12 | 1991-05-28 | Washington University Technology Associates, Inc. | Method for granulation |
-
1987
- 1987-11-09 ES ES198787810646T patent/ES2032205T3/es not_active Expired - Lifetime
- 1987-11-09 AT AT87810646T patent/ATE75394T1/de active
- 1987-11-09 DE DE8787810646T patent/DE3778662D1/de not_active Expired - Lifetime
- 1987-11-09 EP EP87810646A patent/EP0271438B1/de not_active Expired - Lifetime
- 1987-11-12 NZ NZ222525A patent/NZ222525A/xx unknown
- 1987-11-12 CA CA000551655A patent/CA1312016C/en not_active Expired - Lifetime
- 1987-11-12 PT PT86119A patent/PT86119B/pt not_active IP Right Cessation
- 1987-11-13 KR KR1019870012779A patent/KR960002180B1/ko not_active Expired - Fee Related
- 1987-11-13 AU AU81192/87A patent/AU598318B2/en not_active Ceased
- 1987-11-13 IE IE307187A patent/IE60533B1/en not_active IP Right Cessation
- 1987-11-13 JP JP62285627A patent/JP2567427B2/ja not_active Expired - Lifetime
- 1987-11-13 ZA ZA878526A patent/ZA878526B/xx unknown
- 1987-11-13 DK DK595987A patent/DK595987A/da not_active Application Discontinuation
-
1992
- 1992-07-10 GR GR920400683T patent/GR3005132T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA1312016C (en) | 1992-12-29 |
| IE60533B1 (en) | 1994-07-27 |
| DE3778662D1 (de) | 1992-06-04 |
| IE873071L (en) | 1988-05-14 |
| DK595987D0 (da) | 1987-11-13 |
| AU598318B2 (en) | 1990-06-21 |
| JPS63135329A (ja) | 1988-06-07 |
| PT86119B (pt) | 1990-08-31 |
| EP0271438A2 (de) | 1988-06-15 |
| DK595987A (da) | 1988-05-15 |
| KR880005944A (ko) | 1988-07-21 |
| ES2032205T3 (es) | 1993-01-16 |
| AU8119287A (en) | 1988-05-19 |
| ZA878526B (en) | 1988-05-16 |
| GR3005132T3 (enExample) | 1993-05-24 |
| NZ222525A (en) | 1989-12-21 |
| PT86119A (en) | 1987-12-01 |
| KR960002180B1 (ko) | 1996-02-13 |
| EP0271438A3 (en) | 1989-07-19 |
| EP0271438B1 (de) | 1992-04-29 |
| ATE75394T1 (de) | 1992-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2750150B2 (ja) | 改良されたコアー膜付着性質を有する医薬的に許容される活性剤を含む浸透性連続分散性経口投写システム | |
| US4687660A (en) | Pharmaceutical delivery system | |
| US4769027A (en) | Delivery system | |
| TWI233809B (en) | Dosage forms for providing effective reboxetine therapy with once-a-day dosing | |
| US6537573B2 (en) | Combination dosage form comprising cetirizine and pseudoephedrine | |
| FI92648B (fi) | Menetelmä peroraalisen terapeuttisen järjestelmän valmistamiseksi vaikeasti liukeneville vaikuttaville aineille | |
| EP0279976B1 (en) | Pseudoephedrine dosage form | |
| USRE33994E (en) | Pharmaceutical delivery system | |
| JPS61249917A (ja) | 薬剤放出開始時期を制御する手段を備えた浸透圧利用薬剤投与具 | |
| US4915952A (en) | Composition comprising drug, HPC, HPMC and PEO | |
| EP0250374B1 (en) | Therapeutic system for controlled release of drugs | |
| JPS61249916A (ja) | 不活性なコア部を有する浸透圧利用薬剤投与具 | |
| JPS62267221A (ja) | 新規薬物製剤 | |
| JPH0196116A (ja) | 急速な薬剤配送と引続く緩徐な薬剤配送からなる投薬形 | |
| FR2541896A1 (fr) | Dispositif osmotique permettant la disponibilite immediate d'un medicament | |
| PT711146E (pt) | Dispositivos osmoticos com revestimentos permeaveis ao vapor | |
| SE8300577L (sv) | Overdrag som tillforsekrar reglerad avgivning av akriva bestandsdelar fran biologiskt aktiva blandningar, i synnerhet farmaceutiska beredningar, jemte sett att framstella biologiskt aktiva blandningar med reglerad .... | |
| JP2567427B2 (ja) | 浸透分配経口投与製剤 | |
| KR20050071375A (ko) | 조절성 방출 제형 내의 팽창성 삼투 조성물의 형성을 위한(삼투중합체, 삼투제를 포함하는) 코팅 현탁액 및 삼투코팅을 제공하기 위한 상응하는 방법 | |
| JP2002514592A (ja) | 抗うつ剤療法 | |
| US20040058000A1 (en) | Controlled release capsule for delivery of liquid formulation | |
| JP2007520421A (ja) | 経口投与用放出制御型薬物送達システム | |
| JPS63115812A (ja) | 持続性定量薬剤徐放システム | |
| KR900011455A (ko) | 활성제의 서방형 제제 및 그 제조방법 | |
| NO179478B (no) | Fremgangsmåte for fremstilling av multiple enheter med overtrekk som inneholder poredanner |